Lung Cancer
News
Carboplatin, etoposide yield similar survival in NSCLC
Key clinical point: Carboplatin + paclitaxel yielded similar overall survival with fewer adverse effects than etoposide + cisplatin for stage-3...
News
Nivolumab monotherapy reaches advanced squamous NSCLC
Key clinical point: Nivolumab monotherapy shows clinically meaningful efficacy in patients with advanced, heavily pretreated squamous cell NSCLC,...
News
Biopsy remains most costly lung cancer diagnosis tool
Key clinical point: Biopsy costs remain a significant proportion of the overall cost of diagnosing lung cancer. Major finding: 43% of the $38.3...
News
Medicare proposes to cover LDCT screening for lung cancer
News
CMS proposes lung cancer screening with low-dose CT for high-risk patients
News
CheckMate 012: Nivolumab plus chemo less than stellar
Key clinical point: Adding nivolumab to chemotherapy did not enhance overall responses in advanced NSCLC, although there was a suggestion of...
News
Low-dose CT screen for lung cancer cost effective for high-risk patients
Key clinical point: Low-dose CT might be most cost effective for women and current smokers. Major finding: On average, screening for lung cancer...
News
Do small lung adenocarcinomas need subclassifying?
Key clinical point: Comparable 5-year survival rates call into question the need to classify small lung carcinomas as adenocarcinoma in situ vs....
News
VIDEO: Nonclinical factors affect lung resection survival
News
Aggressive radiotherapy dramatically improves limited metastatic NSCLC
Key clinical point: Stereotactic body radiation therapy plus erlotinib dramatically improves survival in limited but progressive metastatic NSCLC...